Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Dec;35(12):3600-3603.
doi: 10.1038/s41375-021-01250-0. Epub 2021 Jun 7.

Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods

Jill Corre #  1 , Aurore Perrot #  1 , Cyrille Hulin  2 , Denis Caillot  3 , Anne-Marie Stoppa  4 , Thierry Facon  5 , Xavier Leleu  6 , Mamoun Dib  7 , Lionel Karlin  8 , Philippe Moreau  9 , Mohamad Mohty  10 , Clara Mariette  11 , Jean Fontan  12 , Jean-Pierre Marolleau  13 , Hélène Demarquette  14 , Borane Slama  15 , Laurent Voillat  16 , Margaret Macro  17 , Frédérique Orsini-Piocelle  18 , Sabine Brechignac  19 , Philippe Rey  20 , Philippe Collet  21 , Mourad Tiab  22 , Karim Belhadj  23 , François Lifermann  24 , Lauriane Clement-Filliatre  25 , Claudine Sohn  26 , Valentine Richez  27 , Hervé Avet-Loiseau  28 ; Intergroupe Francophone du Myélome (IFM)
Affiliations
Multicenter Study

Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods

Jill Corre et al. Leukemia. 2021 Dec.
No abstract available

PubMed Disclaimer

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60. - DOI
    1. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–15. - DOI
    1. Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a Randomised, Open-Label, Phase 3 Trial. Lancet. 2020;395:132–41. - DOI
    1. Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a Randomised, Open-Label, Phase 3 Study. Lancet. 2019;394:29–38. - DOI
    1. Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456–64. - DOI

Publication types

LinkOut - more resources